SS Innovations Files 510(k) Submission for SSi Mantra Surgical Robot with FDA
核心洞察
SS Innovations International Inc. (搜索) submitted a 510(k) premarket notification to the FDA on December 5, 2025, for its SSi Mantra (搜索) surgical robotic system covering multiple specialties including general, urological, colorectal, gynecological, and cardiac surgery (搜索).
The company chose the 510(k) pathway over a De Novo request following FDA discussions, aiming to benefit from potentially faster review timelines and lower costs, with FDA targeting 90-day review completion.
As of November 30, 2025, the SSi Mantra (搜索) has an installed base of 138 systems across eight countries, with 137 hospitals performing over 7,300 procedures including 88 telesurgeries and 390 cardiac surgeries.
SS Innovations International Inc. (搜索) has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its SSi Mantra (搜索) surgical robotic system, marking a significant milestone in the company's expansion into the American market. The December 5, 2025 submission seeks clearance for use across multiple specialty procedures, including general, urological, colorectal, gynecological, and cardiac surgery (搜索).
Strategic Regulatory Approach
The company opted for the 510(k) pathway following a pre-submission meeting and subsequent discussions with the FDA, rather than pursuing a De Novo request. This strategic decision aims to leverage the pathway's potential speed and cost efficiencies for bringing the surgical robotic system to market.
"Our submission of a 510(k) premarket notification to the FDA marks an important milestone in our strategic plan to introduce the company's advanced, cost-efficient SSi Mantra (搜索) surgical robotic system to the U.S. market," said Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations. "Given its affordability, differentiated technology, and proven performance across our existing global installations, we believe the SSi Mantra represents a highly compelling option for hospitals and surgeons in the United States, especially those serving underserved patient communities."
Regulatory Timeline and Global Expansion
The FDA has stated its goal to complete reviews of 510(k) submissions within 90 days of receipt. However, the company noted that approval timing could extend due to factors including the 15-day acceptance review, additional information requests, and response times from the submitter.
Parallel to its U.S. regulatory efforts, SS Innovations continues pursuing European Union CE marking certification for the SSi Mantra (搜索), with expectations of potential approval in the first half of 2026.
Proven Clinical Performance
The SSi Mantra (搜索) has demonstrated substantial clinical adoption globally. As of November 30, 2025, the system's installed base totaled 138 systems across eight countries where regulatory approval has been obtained. A total of 137 hospitals have installed the platform, with over 7,300 surgical procedures completed to date, including 88 telesurgeries and 390 cardiac procedures.
Advanced Technology Features
The SSi Mantra (搜索) surgical robotic system is designed as a user-friendly, modular, multi-arm system featuring 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, and a large 3D 4K monitor. The system includes a touch panel monitor for patient-related information display, virtual real-time imaging of robotic patient-side arm carts, and the capability for superimposition of 3D models from diagnostic imaging.
A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to enhance safety and efficiency. The system utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery (搜索). The SSi Mantra (搜索) has been clinically validated in India across more than 100 different types of surgical procedures.
Market Context and Innovation Trends
The surgical robotics sector continues undergoing rapid transformation driven by advances in imaging, automation, connectivity, and workflow integration. Industry innovators are working to reduce system footprint, broaden procedural applications, and lower per-procedure costs, reshaping expectations for next-generation platforms.
Key developments include system miniaturization through streamlined arms, modular configurations, and improved cable management for easier setup and better access in crowded operating rooms. These changes are particularly significant for community hospitals and ambulatory centers with limited space seeking to adopt robotic capabilities.
Advanced visualization and imaging integration, including high-definition 3D optics, fluorescence guidance, and real-time anatomical mapping, are becoming standard features. Machine learning tools are being incorporated to enhance instrument tracking, reduce tremor, and suggest optimal motion pathways.
Connectivity advances are extending surgical reach through improvements in low-latency communication networks, enabling more reliable remote proctoring and early forms of telesurgery. These capabilities could expand access to subspecialty expertise, particularly in underserved regions.
The industry is placing growing emphasis on cost efficiency, with developers designing systems featuring reusable instruments, simplified maintenance, and lower capital expenditure requirements. Combined with expanding procedural versatility, these approaches aim to make robotic surgery more economically viable for a wider range of facilities.